Human amniotic fluid - Merakris Therapeutics
Alternative Names: Dermacyte; Dermacyte liquid; Dermacyte® Amniotic Wound Care Liquid; MTX-001Latest Information Update: 29 Aug 2025
At a glance
- Originator Merakris Therapeutics
- Developer Department of Veterans Affairs; Merakris Therapeutics
- Class Cell therapies
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Diabetic foot ulcer; Varicose ulcer
- Preclinical Wounds
Most Recent Events
- 19 Aug 2025 USPTO issues a Notice of Allowance for human amniotic fluid in USA
- 26 Mar 2025 Efficacy data from phase-II trial in Varicose ulcer released by Merakris Therapeutics
- 12 Dec 2024 Merakris Therapeutics undertakes an expanded access program for human amniotic fluid in Wounds and Cutaneous ulcers (SC, Injection) (NCT06730022)